Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanimilast Add-on in Uncontrolled Asthma
2022-502208-64-00Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Tanimilast add-on with Placebo add-on (2 arms). Primary endpoint: Number of asthma exacerbations over the 52-week study period. Started Nov 2023; status: completed.
02
Drugs
tanimilast
03
Conditions
asthma
Beyond the preview
Go deeper on 2022-502208-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502208-64-00.